LLY

966.35

+1.98%↑

JNJ

221.39

+0.12%↑

ABBV

202.82

+0.84%↑

UNH

384.32

+1.29%↑

AZN

181.82

-0.27%↓

LLY

966.35

+1.98%↑

JNJ

221.39

+0.12%↑

ABBV

202.82

+0.84%↑

UNH

384.32

+1.29%↑

AZN

181.82

-0.27%↓

LLY

966.35

+1.98%↑

JNJ

221.39

+0.12%↑

ABBV

202.82

+0.84%↑

UNH

384.32

+1.29%↑

AZN

181.82

-0.27%↓

LLY

966.35

+1.98%↑

JNJ

221.39

+0.12%↑

ABBV

202.82

+0.84%↑

UNH

384.32

+1.29%↑

AZN

181.82

-0.27%↓

LLY

966.35

+1.98%↑

JNJ

221.39

+0.12%↑

ABBV

202.82

+0.84%↑

UNH

384.32

+1.29%↑

AZN

181.82

-0.27%↓

Kodu・Aktsiate loetelu・Zai Lab Ltd ADR

Zai Lab Ltd ADR

Avatud

SektorTervishoid

19.32 -2.23

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

19.41

Max

Põhinäitajad
By Trading Economics
Sissetulek	-14M -50M
Müük	12M 128M
Kasumimarginaal	-39.506
Töötajad	1,784
EBITDA	-17M -48M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+74.94% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	6. aug 2026

Turustatistika
By TradingEconomics
Turukapital	174M 2.4B
Eelmine avamishind	21.55
Eelmine sulgemishind	19.32

Uudiste sentiment

By Acuity

25%

75%

75 / 346 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bearish Evidence

28.13 / 31.12 Toetus ja vastupanu

Zai Lab Ltd ADR Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

11. mai 2026, 22:15 UTC

Omandamised, ülevõtmised, äriostud

BMO Financial Group to Sell Transportation-, Vendor-Finance Businesses to Stonepeak

11. mai 2026, 23:46 UTC

Market Talk

Yen Consolidates as Traders Await Bessent's Meetings -- Market Talk

11. mai 2026, 23:44 UTC

Market Talk

Nikkei May Rise on AI Enthusiasm -- Market Talk

11. mai 2026, 23:33 UTC

Market Talk

Gold Rises on Possible Position Adjustments -- Market Talk

11. mai 2026, 22:37 UTC

Market Talk

CSL's Profit, Revenue Downgrade 'Not a Complete Surprise' -- Market Talk

11. mai 2026, 22:32 UTC

Tulu

Verde Clean Fuels 1Q Loss/Shr 5c >VGAS

11. mai 2026, 22:02 UTC

Market Talk

Stellar Auto Sales Increase in Canada Could Be Tied to Return of EV Incentives -- Market Talk

11. mai 2026, 21:49 UTC

Tulu

Rigetti Computing Revenue Triples. Why the Quantum Stock Is Falling. -- Barrons.com

11. mai 2026, 21:42 UTC

Market Talk

Declining Hours Worked Should Keep Bank of Canada Firmly on Hold -- Market Talk

11. mai 2026, 21:32 UTC

Omandamised, ülevõtmised, äriostud

Bank of Montreal to Sell Transportation Finance and Vendor Finance Businesses to Stonepeak

11. mai 2026, 21:32 UTC

Omandamised, ülevõtmised, äriostud

BMO: Supports Strategy to Elevate Returns and Accelerate Growth, Transaction Accretive to Cap Ratios and ROE >BMO.T

11. mai 2026, 21:32 UTC

Omandamised, ülevõtmised, äriostud

BMO: Positions Businesses for Continued Growth in Efficient Cap Structure >BMO.T

11. mai 2026, 21:32 UTC

Omandamised, ülevõtmised, äriostud

BMO: To Invest in 19.9% Equity Interest, Enabling Continued Participation in the Businesses' Long-Term Value Creation >BMO.T

11. mai 2026, 21:31 UTC

Omandamised, ülevõtmised, äriostud

BMO: Announces Strategic Sale of Transportation and Vendor Finance Businesses

11. mai 2026, 21:23 UTC

Omandamised, ülevõtmised, äriostud

CSG Systems Sale to NEC Gets CFIUS Clearance

11. mai 2026, 21:12 UTC

Tulu

Ovintiv: Full-Yr Production Volumes Expected to Avg 620 to 645 MBOE/d, Full-Yr Expected Cap Investment of $2.25B to $2.35B >OVV

11. mai 2026, 21:12 UTC

Tulu

Ovintiv 1Q Loss/Shr $2.35 >OVV

11. mai 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

11. mai 2026, 20:44 UTC

Tulu

Steris: Board Approves New $1B Shr Repurchase Program >STE

11. mai 2026, 20:43 UTC

Tulu

Whirlpool Shares Are Still Falling. Last Week's Earnings Might Be Why. -- Barrons.com

11. mai 2026, 20:32 UTC

Tulu

CleanSpark 2Q Loss/Shr $1.52 >CLSK

11. mai 2026, 20:32 UTC

Tulu

CleanSpark 2Q Rev $136.4M >CLSK

11. mai 2026, 20:30 UTC

Tulu

Hims & Hers Stock Sinks. Why Earnings Offered Wall Street a Big Surprise. -- Barrons.com

11. mai 2026, 20:30 UTC

Tulu

Steris 4Q Cont Ops EPS $2.24 >STE

11. mai 2026, 20:30 UTC

Tulu

Steris 4Q Rev $1.6B >STE

11. mai 2026, 20:30 UTC

Tulu

Steris Sees FY Adj EPS $11.10-Adj EPS $11.30 >STE

11. mai 2026, 20:30 UTC

Tulu

Steris 4Q Adj EPS $2.83 >STE

11. mai 2026, 20:22 UTC

Kuumad aktsiad

Stocks to Watch: Moderna, Intel, Micron, Fox -- WSJ

11. mai 2026, 19:37 UTC

Tulu

More Bad News at KKR's Private Credit Fund -- Barrons.com

11. mai 2026, 19:32 UTC

Market Talk

Oil Gains As Trump Rejects Iran's Response to U.S. Plan -- Market Talk

Võrdlus sarnastega

Hinnamuutus

Zai Lab Ltd ADR Prognoos

Hinnasiht

By TipRanks

74.94% tõus

12 kuu keskmine prognoos

Keskmine 34.27 USD 74.94%

Kõrge 44 USD

Madal 21.8 USD

Põhineb 4 Wall Streeti analüütiku instrumendi Zai Lab Ltd ADR 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

4 ratings

Osta

Hoia

Müü

Põhineb 4 analüütiku instrumendi Zai Lab Ltd ADR aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

28.13 / 31.12Toetus ja vastupanu

Recent bearish events outweigh bullish events.

All events are bullish.

Sentiment

By Acuity

75 / 346 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Zai Lab Ltd ADR

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT; and strategic collaboration with Pfizer for XACDURO. The company was incorporated in 2013 and is headquartered in Shanghai, China.